There’s information. And then there’s intelligence.

PharmSource’s accurate, insightful Trend Reports provide context and meaning that’s critical to decision-makers in the bio/pharma contract services arena. Our experts identify trends and forecast changes – delivering the knowledge and understanding necessary to achieve optimal strategic outcomes.

Follow the Money: The Outlook for Outsourced Spending on Early Development Services

Demand for development services to support Phase 1 and Phase 2 clinical trials is driving double-digit growth for CROs and CDMOs.

Demand for clinical manufacturing services is actually outstripping industry capacity and leading to delays in…

Learn more

Bio/Pharma CapEx Trends 2016

Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry.

Having spent over $150 billion for new plant and equipment in the past 5 years, it’s clear that global bio/pharma companies would rather…

Learn more

Contract Manufacturing Market Opportunities for Antibody Drug Conjugates

This expert trend report is an indispensable resource for understanding the technical developments in the Antibody Drug Conjugate (ADC) sector and the scale of the commercial opportunities and risks for CMOs.

The CDMO sector is investing significant resources to expand its capabilities in the ADC arena. More than 20 companies are active in the sector although, to date, no single company…

Learn more

Catching a Wave: How Much Will CMOs Benefit From Biosimilars?

Regulatory developments in the United States, coupled with impending patent expiry, have paved the way for the introduction of biosimilars of increasing technical complexity. In the European Union, 20 first wave biosimilars, consisting of growth hormones and relatively simple recombinant proteins, have already been approved. Of those first wave biosimilars…

Learn more

Opportunity Knocks:
In-Licensed Drug Products Can Signal Outsourcing Opportunity

Of the more than 230 New Molecular Entities (NMEs) approved between 2003-2013, over one-third were in-licensed by the sponsor receiving the approval. A significant difference in manufacturing status emerged between…

Learn more

CDMO and CRO Outlook: Robust Market Conditions Augur Growth, More M&A Activity Ahead

Emerging bio/pharmaceutical companies are benefitting from a surge in financing from venture capital, IPOs and secondary offerings. Funding raised in the first half of 2014 is double what was raised in the same period of 2013. R&D spending by global bio/pharma companies, including funds supporting emerging company partners, continues to…

Learn more